Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma

Tarunpreet Bains, Andy Chen, Andrew Lemieux, Brandon Hayes-Lattin, Jose F. Leis, William Dibb, Richard Maziarz

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

High-dose therapy with autologous stem cell transplant (autoSCT) is standard therapy for relapsed/refractory Hodgkin lymphoma, although the optimal conditioning regimen remains uncertain. We conducted a retrospective analysis of 100 consecutive patients with relapsed/refractory Hodgkin lymphoma who underwent autoSCT between 1998 and 2009. There were 60 patients who received busulfan, melphalan and thiotepa (BuMelTt) conditioning and 40 who received other common regimens. There were no significant differences in patient characteristics between the two groups. With a median follow-up of 4.3 years, the 5-year overall survival (OS) was superior for patients who received BuMelTt versus other conditioning (73% vs. 44%, p = 0.05). BuMelTt was also associated with an improved 5-year progression-free survival (66% vs. 37%, p = 0.03). There were no differences in length of hospitalization, febrile neutropenia, hepatic veno-occlusive disease or 100-day non-relapse mortality (NRM). There were more cases of severe mucositis but fewer episodes of bacteremia with BuMelTt. Our results suggest that BuMelTt may be a superior conditioning regimen for autoSCT in Hodgkin lymphoma.

Original languageEnglish (US)
Pages (from-to)583-587
Number of pages5
JournalLeukemia and Lymphoma
Volume55
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Thiotepa
Busulfan
Melphalan
Hematopoietic Stem Cells
Hodgkin Disease
Transplants
Stem Cells
Hepatic Veno-Occlusive Disease
Febrile Neutropenia
Mucositis
Bacteremia
Disease-Free Survival
Hospitalization
Survival
Mortality
Therapeutics

Keywords

  • Autologous transplant
  • Busulfan
  • Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. / Bains, Tarunpreet; Chen, Andy; Lemieux, Andrew; Hayes-Lattin, Brandon; Leis, Jose F.; Dibb, William; Maziarz, Richard.

In: Leukemia and Lymphoma, Vol. 55, No. 3, 03.2014, p. 583-587.

Research output: Contribution to journalArticle

@article{a2b2f2d7205d4daabbf88456747729eb,
title = "Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma",
abstract = "High-dose therapy with autologous stem cell transplant (autoSCT) is standard therapy for relapsed/refractory Hodgkin lymphoma, although the optimal conditioning regimen remains uncertain. We conducted a retrospective analysis of 100 consecutive patients with relapsed/refractory Hodgkin lymphoma who underwent autoSCT between 1998 and 2009. There were 60 patients who received busulfan, melphalan and thiotepa (BuMelTt) conditioning and 40 who received other common regimens. There were no significant differences in patient characteristics between the two groups. With a median follow-up of 4.3 years, the 5-year overall survival (OS) was superior for patients who received BuMelTt versus other conditioning (73{\%} vs. 44{\%}, p = 0.05). BuMelTt was also associated with an improved 5-year progression-free survival (66{\%} vs. 37{\%}, p = 0.03). There were no differences in length of hospitalization, febrile neutropenia, hepatic veno-occlusive disease or 100-day non-relapse mortality (NRM). There were more cases of severe mucositis but fewer episodes of bacteremia with BuMelTt. Our results suggest that BuMelTt may be a superior conditioning regimen for autoSCT in Hodgkin lymphoma.",
keywords = "Autologous transplant, Busulfan, Hodgkin lymphoma",
author = "Tarunpreet Bains and Andy Chen and Andrew Lemieux and Brandon Hayes-Lattin and Leis, {Jose F.} and William Dibb and Richard Maziarz",
year = "2014",
month = "3",
doi = "10.3109/10428194.2013.806659",
language = "English (US)",
volume = "55",
pages = "583--587",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma

AU - Bains, Tarunpreet

AU - Chen, Andy

AU - Lemieux, Andrew

AU - Hayes-Lattin, Brandon

AU - Leis, Jose F.

AU - Dibb, William

AU - Maziarz, Richard

PY - 2014/3

Y1 - 2014/3

N2 - High-dose therapy with autologous stem cell transplant (autoSCT) is standard therapy for relapsed/refractory Hodgkin lymphoma, although the optimal conditioning regimen remains uncertain. We conducted a retrospective analysis of 100 consecutive patients with relapsed/refractory Hodgkin lymphoma who underwent autoSCT between 1998 and 2009. There were 60 patients who received busulfan, melphalan and thiotepa (BuMelTt) conditioning and 40 who received other common regimens. There were no significant differences in patient characteristics between the two groups. With a median follow-up of 4.3 years, the 5-year overall survival (OS) was superior for patients who received BuMelTt versus other conditioning (73% vs. 44%, p = 0.05). BuMelTt was also associated with an improved 5-year progression-free survival (66% vs. 37%, p = 0.03). There were no differences in length of hospitalization, febrile neutropenia, hepatic veno-occlusive disease or 100-day non-relapse mortality (NRM). There were more cases of severe mucositis but fewer episodes of bacteremia with BuMelTt. Our results suggest that BuMelTt may be a superior conditioning regimen for autoSCT in Hodgkin lymphoma.

AB - High-dose therapy with autologous stem cell transplant (autoSCT) is standard therapy for relapsed/refractory Hodgkin lymphoma, although the optimal conditioning regimen remains uncertain. We conducted a retrospective analysis of 100 consecutive patients with relapsed/refractory Hodgkin lymphoma who underwent autoSCT between 1998 and 2009. There were 60 patients who received busulfan, melphalan and thiotepa (BuMelTt) conditioning and 40 who received other common regimens. There were no significant differences in patient characteristics between the two groups. With a median follow-up of 4.3 years, the 5-year overall survival (OS) was superior for patients who received BuMelTt versus other conditioning (73% vs. 44%, p = 0.05). BuMelTt was also associated with an improved 5-year progression-free survival (66% vs. 37%, p = 0.03). There were no differences in length of hospitalization, febrile neutropenia, hepatic veno-occlusive disease or 100-day non-relapse mortality (NRM). There were more cases of severe mucositis but fewer episodes of bacteremia with BuMelTt. Our results suggest that BuMelTt may be a superior conditioning regimen for autoSCT in Hodgkin lymphoma.

KW - Autologous transplant

KW - Busulfan

KW - Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84894493105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894493105&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.806659

DO - 10.3109/10428194.2013.806659

M3 - Article

C2 - 23697844

AN - SCOPUS:84894493105

VL - 55

SP - 583

EP - 587

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -